Limited external irradiation and interstitial 192iridium implant in the treatment of squamous cell carcinoma of the tonsillar region.
Between January 1976 and March 1982, 80 patients with histologically proven diagnosis of squamous cell carcinoma of the tonsillar region were treated with definitive radiotherapy. Sixty-five (81%) of these patients had locally advanced tumors (Stage III and IV); 49% of patients had clinically palpable cervical lymphadenopathy. All patients received a combined external megavoltage and interstitial irradiation. The dose of external irradiation was limited to 4500-5000 cGy over 41/2 to 51/2 weeks. This was followed by interstitial 192iridium implants to doses of 2000-2500 cGy in 50-60 hours for T1, T2 lesions and 3000-4000 cGy in 60-100 hours for T3 , T4 lesions. The neck masses were also separately implanted to deliver additional doses of 2000-4000 cGy in 50-80 hours. Overall local tumor control was observed in 84% of patients with a minimum follow-up period of 2 years. An absolute 3-year disease free survival of the entire group was 72%. Treatment related complications such as soft tissue necrosis or osteoradionecrosis occurred in 6% (5/80) of patients. The salvage of neck failures and local failures was possible in 78 and 38% of patients, respectively, either by surgery or by re-irradiation employing interstitial 192iridium implants. Functional and esthetic integrity was well preserved in most cases.
D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000295:instrumentation; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007495:Iridium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010157:Palatal Neoplasms / Q000532:radiotherapy; D010160:Palate, Soft; D011868:Radioisotopes / Q000627:therapeutic use*; D011882:Radiotherapy, High-Energy; D014067:Tonsillar Neoplasms / Q000532:radiotherapy*
D011868:Radioisotopes; D007495:Iridium